A Phase 3 interventional study of APL-130277 and subcutaneous apomorphine in Motor OFF Episodes Associated With Parkinson's Disease, sponsored by Sumitomo Pharma America, Inc.. Completed at 31 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-16.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing apomorphine in Parkinson Disease — 1 open to participants now, 2 under way, 1 of them phase 3. Apomorphine · Parkinson Disease.
Among the 32 studies testing apomorphine in Parkinson Disease, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 12 in phase 3, and was the 28th registered.
4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →1 of the 32 studies testing apomorphine in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–89
By country, each count listing its studies:
Apomorphine: first FDA approval 2004 (APOKYN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 14 · Phase 4 5
First in 1999; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 40 across 3,358 interventional studies indexed under Parkinson Disease.
Median enrollment 42 across the 32 interventional studies. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 8 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing apomorphine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes)
An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations.
PART A consists of an open label, crossover titration phase where eligible subjects will be randomized to 1 of 2 treatment sequences in a 1:1 ratio to Sublingual APL-130277 followed by subcutaneous apomorphine or subcutaneous apomorphine followed by sublingual APL-130277. Subjects will undergo dose titration with the first study treatment (APL-130277 or sc apomorphine) to tolerance and effect, ie, the tolerable dose that turns the subject from the practically defined "OFF" state to the full "ON" state as determined by both the Investigator and subject. The subject will then be crossed over to the other study treatment (APL-130277 or subcutaneous apomorphine) and similarly titrated to tolerance and effect. These determined doses of APL-130277 and subcutaneous apomorphine will be used during PART B.
PART B consists of an open-label, crossover treatment period where subjects will be randomized to one of the study treatment for 4 weeks, then be crossed over to the other study treatment (APL-130277 or sc apomorphine) for additional 4-weeks of open-label treatment. Subjects return to the clinic for safety and efficacy assessments throughout the treatment period.
This study is designed to test the superiority of sublingually administered APL-130277 against subcutaneously injected apomorphine (APO-go) for the treatment of "OFF" episodes in patients with Parkinson's Disease, as measured by the change from pre-dose to 90 minutes post-dose in MDS UPDRS Part III score in Part B after 4 weeks of dosing in each crossover period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with type 1 diabetes, or insulin dependent diabetics are excluded. Subjects with type 2 diabetes are eligible for study inclusion if the following conditions are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
Drug: APL-130277
subcutaneous apomorphine , Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
Drug: subcutaneous apomorphine
APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
Also known as: Apomorphine Hydrochloride
subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
Also known as: APO-go®
Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B).
The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society. The summary score used in this study for the primary objective and primary efficacy endpoint is Part III motor examination score. Each Part III item has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse motor function. MDS-UPDRS III is a total of 18 questions with 33 individual items, each item ranges from 0-4. The MDS-UPDRS III motor score is the summation of all these 33 individual item scores, and hence ranges from 0-132. Score drops over time imply improvement in motor function (higher values represent a worse outcome).
Time frame: Pre-dose to 90 minutes post-dose at Week 4 of each treatment period (Visit 3 and 6)
Durability of Effect, Defined as an Investigator Confirmed Full "ON" Within 30 Minutes Post Dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B).
Investigator will confirm whether subject is "OFF", Full "ON" or Partial "ON" , and note the time the subject changes from "OFF" to Partial "ON" or Full "ON". The Investigator will also record the subject "ON"/"OFF" status (binary variable, Yes / No) prior to performing each MDS-UPDRS Part III assessment. Durability of effect is defined as an Investigator confirmed full "ON" within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks of dosing in each PART B crossover period. Response rate = % of subjects that achived full "ON" within the timeframe
Time frame: Within 30 minutes post-dose and at 90 minutes post-dose at Week 4 of each treatment period (Visit 3 and 6)
Subject Preference for APL Treatment as Measured by the Subject Treatment Preference Questionnaire (TPQ), Planned After the Subject Had Completed Both APL-130277 and sc Apomorphine Treatment Regimens (Assessed In-clinic at Visit 6 of PART B)
The TPQ assessment of subject treatment preference was changed from being based on a visual analogue scale or VAS (Q9b)) to a 5-point Likert scale (Q9a). Subject reported preference for APL or SC was based on question Q9a or Q9b combined. For Q9a, responses were dichotomized as follows for statistical analysis: preference for APL (responses of either definitely or somewhat prefer APL) versus no preference for APL (responses of no preference, or somewhat/definitely prefer sc apomorphine). The VAS score was similarly dichotomized as preference for APL (score of \>0 to 50) versus no preference for APL (-50 to 0). If a subject responded to both Q9a and Q9b, then Q9a only was used.
Time frame: After 8 weeks of treatment (Visit 6)
Subject Confirmed Durability of Effect, Defined as Subject Confirmed Full "ON" Within 30 Minutes Post-dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B).
Patients will confirm whether he/she is "OFF", Full "ON" or Partial "ON", and the staff will ask the subject to notify the staff when he/she changes from "OFF" to Partial "ON" or Full "ON" (binary variable, Yes / No) . Subject confirmed durability of effect is defined as subject confirmed full "ON" within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks of dosing in each crossover period (assessed in-clinic at V3 and V6 of PART B). Response rate = % subjects that achived full ON within the timeframe
Time frame: Week 4
Patient Global Impression of Change (PGI-C): Subject Improvement of "OFF" Episodes, Defined as Very Much Better, Much Better or a Little Better After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B).
The PGI-C is the patient reported outcome counterpart to the Clinical Global Impressions scale, (CGI), which was published in 1976 by the National Institute of Mental Health (US). It consists of one item taken from the CGI and adapted to the patient. The PGI-C is based on a 7-point scale, where a lower score is associated with higher symptom improvement. The scale is: Very much better Much better A little better No change A little worse Much worse Very much worse Subject improvement of "OFF" episodes is defined as very much better, much better or a little better at Week 4 in each PART B crossover period. Response rate= % of subjects who achieved improvement of "OFF" episodes
Time frame: At Week 4 of each treatment period (Visit 3 and 6, or Early Termination)
| Milestone | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL |
|---|---|---|---|---|---|---|
| Started | 20 | 19 | 19 | 18 | 18 | 19 |
| Safety population | 20 | 18 | 19 | 18 | 18 | 19 |
| Modified intent-to-treat population | 20 | 18 | 19 | 18 | 18 | 19 |
| Completed | 0 | 0 | 16 | 15 | 14 | 15 |
| Not completed | 20 | 19 | 3 | 3 | 4 | 4 |
| Withdrew: Adverse event | 3 | 6 | 1 | 1 | 3 | 1 |
| Withdrew: Lack of efficacy | 13 | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 2 | 2 | 1 | 3 |
| Withdrew: Early term at sponsor request | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL |
|---|---|---|---|---|---|---|
| Started | 20 | 19 | 19 | 18 | 18 | 19 |
| Safety population part a | 20 | 18 | 19 | 18 | 18 | 19 |
| Modified intent-to-treat population part a | 20 | 18 | 19 | 18 | 18 | 19 |
| Completed | 2 | 3 | 19 | 18 | 18 | 19 |
| Not completed | 18 | 16 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 12 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Early term at sponsor request | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL |
|---|---|---|---|---|---|---|
| Started | 2 | 3 | 19 | 18 | 18 | 19 |
| Completed | 0 | 0 | 19 | 18 | 18 | 19 |
| Not completed | 2 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 19 | 18 | 18 | 19 |
| Safety population part b | 0 | 0 | 19 | 18 | 18 | 19 |
| Modified intent-to-treat population part b | 0 | 0 | 19 | 18 | 18 | 19 |
| Completed | 0 | 0 | 16 | 15 | 14 | 15 |
| Not completed | 0 | 0 | 3 | 3 | 4 | 4 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 2 | 1 | 3 |
The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society. The summary score used in this study for the primary objective and primary efficacy endpoint is Part III motor examination score. Each Part III item has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse motor function. MDS-UPDRS III is a total of 18 questions with 33 individual items, each item ranges from 0-4. The MDS-UPDRS III motor score is the summation of all these 33 individual item scores, and hence ranges from 0-132. Score drops over time imply improvement in motor function (higher values represent a worse outcome).
| Units on a scale | SC (Subcutaneous Apomorphine) | APL (APL-130277) |
|---|---|---|
| Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B). | -13.78 (-16.65 to -10.90) | -13.55 (-16.39 to -10.70) |
Investigator will confirm whether subject is "OFF", Full "ON" or Partial "ON" , and note the time the subject changes from "OFF" to Partial "ON" or Full "ON". The Investigator will also record the subject "ON"/"OFF" status (binary variable, Yes / No) prior to performing each MDS-UPDRS Part III assessment. Durability of effect is defined as an Investigator confirmed full "ON" within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks of dosing in each PART B crossover period. Response rate = % of subjects that achived full "ON" within the timeframe
| Percentage of participants | SC (Subcutaneous Apomorphine) | APL (APL-130227) |
|---|---|---|
| Durability of Effect, Defined as an Investigator Confirmed Full "ON" Within 30 Minutes Post Dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B). | 18.03 | 17.74 |
The TPQ assessment of subject treatment preference was changed from being based on a visual analogue scale or VAS (Q9b)) to a 5-point Likert scale (Q9a). Subject reported preference for APL or SC was based on question Q9a or Q9b combined. For Q9a, responses were dichotomized as follows for statistical analysis: preference for APL (responses of either definitely or somewhat prefer APL) versus no preference for APL (responses of no preference, or somewhat/definitely prefer sc apomorphine). The VAS score was similarly dichotomized as preference for APL (score of \>0 to 50) versus no preference for APL (-50 to 0). If a subject responded to both Q9a and Q9b, then Q9a only was used.
| % of participants | Overall |
|---|---|
| Subject Preference for APL Treatment as Measured by the Subject Treatment Preference Questionnaire (TPQ), Planned After the Subject Had Completed Both APL-130277 and sc Apomorphine Treatment Regimens (Assessed In-clinic at Visit 6 of PART B) | 72.2 (61.9 to 82.6) |
Patients will confirm whether he/she is "OFF", Full "ON" or Partial "ON", and the staff will ask the subject to notify the staff when he/she changes from "OFF" to Partial "ON" or Full "ON" (binary variable, Yes / No) . Subject confirmed durability of effect is defined as subject confirmed full "ON" within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks of dosing in each crossover period (assessed in-clinic at V3 and V6 of PART B). Response rate = % subjects that achived full ON within the timeframe
| Percentage of participants | SC (Subcutaneous Apomorphine) | APL (APL-130227) |
|---|---|---|
| Subject Confirmed Durability of Effect, Defined as Subject Confirmed Full "ON" Within 30 Minutes Post-dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B). | 14.75 | 19.36 |
The PGI-C is the patient reported outcome counterpart to the Clinical Global Impressions scale, (CGI), which was published in 1976 by the National Institute of Mental Health (US). It consists of one item taken from the CGI and adapted to the patient. The PGI-C is based on a 7-point scale, where a lower score is associated with higher symptom improvement. The scale is: Very much better Much better A little better No change A little worse Much worse Very much worse Subject improvement of "OFF" episodes is defined as very much better, much better or a little better at Week 4 in each PART B crossover period. Response rate= % of subjects who achieved improvement of "OFF" episodes
| Percentage of participants | SC (Subcutaneous Apomorphine) | APL (APL-130277) |
|---|---|---|
| Patient Global Impression of Change (PGI-C): Subject Improvement of "OFF" Episodes, Defined as Very Much Better, Much Better or a Little Better After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B). | 77.14 | 83.10 |
Collected over 10 weeks (from first dose of study drug to last study visit). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Dose Titration: APL (APL-130277) | 0/102 (0%) | 0/102 (0%) | 52/102 (51%) |
| Part A Dose Titration: SC (Subcutaneous Apomorphine) | 0/97 (0%) | 1/97 (1%) | 44/97 (45.4%) |
| Part B Treatment: APL (APL-130277) | 0/71 (0%) | 1/71 (1.4%) | 23/71 (32.4%) |
| Part B Treatment: SC (Subcutaneous Apomorphine) | 0/70 (0%) | 1/70 (1.4%) | 37/70 (52.9%) |
| Event | Part A Dose Titration: APL (APL-130277) | Part A Dose Titration: SC (Subcutaneous Apomorphine) | Part B Treatment: APL (APL-130277) | Part B Treatment: SC (Subcutaneous Apomorphine) |
|---|---|---|---|---|
| Foot fractureInjury, poisoning and procedural complications | 0/102 | 0/97 | 0/71 | 1/70 |
| Intestinal obstructionGastrointestinal disorders | 0/102 | 0/97 | 1/71 | 0/70 |
| Intestinal ischaemiaGastrointestinal disorders | 0/102 | 1/97 | 0/71 | 0/70 |
| Event | Part A Dose Titration: APL (APL-130277) | Part A Dose Titration: SC (Subcutaneous Apomorphine) | Part B Treatment: APL (APL-130277) | Part B Treatment: SC (Subcutaneous Apomorphine) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 32/102 | 22/97 | 10/71 | 11/70 |
| Injection site haematomaGeneral disorders | 0/102 | 2/97 | 0/71 | 19/70 |
| DyskinesiaNervous system disorders | 8/102 | 7/97 | 8/71 | 14/70 |
| SomnolenceNervous system disorders | 9/102 | 13/97 | 3/71 | 4/70 |
| FatigueGeneral disorders | 6/102 | 10/97 | 4/71 | 4/70 |
| DizzinessNervous system disorders | 10/102 | 4/97 | 2/71 | 3/70 |
| Injection site erythemaGeneral disorders | 0/102 | 6/97 | 1/71 | 5/70 |
| Orthostatic hypotensionVascular disorders | 4/102 | 5/97 | 3/71 | 4/70 |
| FallInjury, poisoning and procedural complications | 1/102 | 1/97 | 4/71 | 1/70 |
| YawningRespiratory, thoracic and mediastinal disorders | 3/102 | 5/97 | 0/71 | 1/70 |
| Age, Categorical(Participants) | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 8 | 8 | 10 | 9 | 8 | 52 |
| >=65 years | 11 | 10 | 11 | 8 | 9 | 11 | 60 |
| Age, Continuous(Years) | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| Mean | 64.9 ± 8.33 | 63.9 ± 9.99 | 65.0 ± 9.80 | 63.2 ± 6.91 | 63.4 ± 9.71 | 65.6 ± 8.69 | 64.4 ± 8.80 |
| Sex: Female, Male(Participants) | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 7 | 6 | 1 | 6 | 7 | 34 |
| Male | 13 | 11 | 13 | 17 | 12 | 12 | 78 |
| Ethnicity (NIH/OMB)(Participants) | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 1 | 1 | 2 | 1 | 8 |
| Not Hispanic or Latino | 19 | 15 | 18 | 16 | 16 | 18 | 102 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 20 | 18 | 19 | 18 | 18 | 19 | 112 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Country(Participants) | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| Austria | 1 | 0 | 2 | 1 | 1 | 0 | 5 |
| Germany | 6 | 2 | 8 | 10 | 5 | 10 | 41 |
| Spain | 7 | 8 | 4 | 3 | 5 | 4 | 31 |
| France | 1 | 1 | 0 | 0 | 0 | 1 | 3 |
| United Kingdom | 1 | 1 | 1 | 3 | 2 | 3 | 11 |
| Italy | 4 | 6 | 4 | 1 | 5 | 1 | 21 |
| Baseline Height (cm)(cm) | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| Mean | 168.05 ± 12.626 | 165.62 ± 12.348 | 171.91 ± 10.260 | 174.78 ± 6.632 | 170.94 ± 9.795 | 171.16 ± 9.929 | 170.39 ± 10.652 |
| Baseline Weight (kg)(kg) | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| Mean | 74.25 ± 16.151 | 70.91 ± 18.624 | 78.45 ± 21.893 | 80.31 ± 11.691 | 83.26 ± 24.383 | 77.14 ± 15.284 | 77.34 ± 18.470 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual Patient Data (IPD) for this study may be made available upon request via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: IPD will be made available upon request within 12 months of posting the study results on ct.gov.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Dec 2018 to primary completion in Aug 2021, 31 months.
Results were first posted in Dec 2022, 1 year 4 months after primary completion.
Of 40 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 31 months is close to that.
Counting every sponsor, half of 68 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apomorphine
Sumitomo Pharma America, Inc. →